GLP-1 Medications for Weight Loss: What to Expect at Dr. Qureshi's Katy Office

What are GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1. The medications in this class — technically GLP-1 receptor agonists — mimic a natural gut hormone your body releases after eating that signals fullness to the brain and helps regulate blood sugar. They were originally developed as treatments for type 2 diabetes, where their ability to lower blood sugar made them a useful alternative or addition to other diabetes medications.

Researchers and clinicians noticed something consistent in diabetic patients taking these drugs: they were also losing meaningful amounts of weight. That observation led to dedicated clinical trials of higher-dose GLP-1 formulations specifically for weight management, and the FDA has since approved several for chronic weight management in patients with obesity or weight-related health conditions.

The two GLP-1 medications most widely used for weight loss today are Semaglutide and Tirzepatide. Semaglutide acts on the GLP-1 receptor only. Tirzepatide is a newer dual-action drug that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which appears to produce greater average weight loss in some patients in clinical comparisons. Both medications are FDA-approved for weight management when prescribed at the appropriate dose for that indication. At Dr. Qureshi's Katy office, GLP-1 medications complement his interventional pain and regenerative medicine services — recognizing that excess weight contributes meaningfully to joint pain, back pain, and mobility issues for many patients.

How do GLP-1 medications cause weight loss?

GLP-1 medications work through several connected mechanisms. The most important for weight loss is appetite suppression: the medication acts on receptors in the brain to increase the sensation of fullness and reduce hunger signals. Most patients simply think about food less and feel satisfied with smaller portions.

The second mechanism is delayed gastric emptying. Food stays in the stomach longer, prolonging the feeling of fullness after a meal — part of why most patients eat less without feeling deprived. A third effect, particularly relevant for patients with insulin resistance or pre-diabetes, is improved insulin sensitivity and better blood sugar control. By smoothing out post-meal blood sugar spikes, GLP-1 medications support a metabolic environment that favors weight loss rather than storage.

The effect scales with dose. Patients start at a low dose and titrate up over several weeks — gradual increases reduce side effects and give the body time to adapt. The NIH treatment guidelines for obesity recognize anti-obesity medications, including GLP-1 agonists, as appropriate medical interventions for patients who meet specific clinical criteria.

Who is a candidate for GLP-1 weight loss treatment?

GLP-1 medications are not appropriate for everyone, but they are an option for a wide range of patients who have struggled with weight management. The general clinical criteria mirror the FDA-approved labeling and broader chronic weight management guidelines. Most patients considered for GLP-1 therapy meet at least one of the following:

• BMI of 30 or higher (clinical obesity)
• BMI of 27 or higher with at least one weight-related health condition — for example, type 2 diabetes, hypertension, high cholesterol, sleep apnea, or fatty liver disease
• Have tried lifestyle changes (diet and exercise) without sustained results
• Are seeking medical, non-surgical weight management as an alternative to bariatric surgery
• Have no contraindications to GLP-1 medications (see below)

The best candidates are patients ready to commit to ongoing treatment, regular monitoring, and reasonable lifestyle adjustments. GLP-1 medications work best when paired with consistent eating patterns, hydration, and at least light physical activity.

What's the difference between Semaglutide and Tirzepatide?

Both Semaglutide and Tirzepatide are weekly injectable medications, self-administered at home in the abdomen, thigh, or upper arm. They share the same general goal — reduce appetite and support weight loss — but they have meaningful differences.

Semaglutide (branded as Wegovy for weight loss and Ozempic for diabetes) has the longer track record. The FDA approved Semaglutide for chronic weight management in 2021, after large clinical trials demonstrated significant and sustained weight loss in patients with obesity. Tirzepatide (branded as Zepbound for weight loss and Mounjaro for diabetes) is newer and acts on two receptors instead of one (GLP-1 plus GIP). Head-to-head clinical trials have generally shown greater average weight loss with Tirzepatide compared with Semaglutide, though individual response varies considerably.

The choice between them is individualized. Dr. Qureshi considers your medical history, prior medication responses, side effect tolerance, and insurance considerations when recommending one over the other. For some patients, switching from one to the other after a plateau or side effect issue is the right call.

What does the program look like at Dr. Qureshi's office?

The GLP-1 weight loss program at Dr. Qureshi's Katy office is structured to be straightforward and convenient. Most patients only need one in-person visit at the start; ongoing follow-up is virtual.

Initial in-office consultation. Your first appointment includes a full medical history review, vital signs, BMI calculation, and discussion of your weight loss goals. Dr. Qureshi reviews contraindications, current medications, and previous weight loss attempts. Bloodwork is ordered to establish baseline metabolic markers (fasting glucose, A1c, lipid panel, kidney function, thyroid). For more on the practice, see about Dr. Qureshi.

Prescription and titration. Once bloodwork is back and contraindications have been ruled out, Dr. Qureshi prescribes generic compounded Semaglutide or Tirzepatide at a low starting dose, with planned titration up over several weeks. The program uses generic compounded versions specifically because they make ongoing treatment financially accessible — not brand-name retail products like Wegovy or Zepbound.

Virtual follow-up. After the initial in-office visit, ongoing follow-up appointments are virtual — you don't need to drive to the office for routine check-ins. Periodic bloodwork and weight monitoring continue throughout treatment.

One important note: nutrition coaching is not included. Dr. Qureshi prescribes and monitors the medication and tracks clinical progress. Patients who want structured nutrition counseling can be referred to dietitians or complementary programs. For insurance questions related to the consultation visit, see the insurance page.

What weight loss can I realistically expect?

GLP-1 medications work, but they are not magic and individual results vary widely. Setting realistic expectations is part of a successful program.

Most patients see noticeable weight loss within the first month, often as the appetite-suppressing effect kicks in. Average weight loss is typically 5-10 pounds per month in the early months. Long-term clinical trial data shows that patients on continuous GLP-1 therapy can lose up to 25% of their body weight after 72 weeks of consistent treatment — a result comparable to some bariatric surgery outcomes.

Several factors influence how much you'll lose: starting weight, medication and dose, adherence to the weekly injection schedule, baseline metabolism, and whether food intake actually decreases. Plateaus are normal — after several months of steady loss, the rate often slows. When this happens, Dr. Qureshi may adjust the dose, consider switching medications, or evaluate other factors (sleep, stress, other medications).

One important caveat: weight regain is common when patients stop the medication. The appetite-suppressing effect ends when the drug clears the system, and many patients regain a substantial portion of the lost weight within a year of stopping unless they have made durable lifestyle changes. Long-term planning is built into the program from the beginning.

What are the common side effects?

Most patients tolerate GLP-1 medications well, but side effects are common — especially during the first few weeks and after each dose increase.

Most common side effects are gastrointestinal:

• Nausea — often mild, usually improves within 1-2 weeks of starting or increasing the dose
• Mild vomiting — typically infrequent and improves with time
• Constipation or diarrhea — staying hydrated and eating fiber helps
• Reduced appetite — the intended effect, but can feel more dramatic than expected initially
• Mild stomach pain or bloating

These GI effects are typically self-limited and improve as the body adjusts. Slower titration, smaller meals, avoiding rich or greasy foods, and staying hydrated all help. Most patients adapt within the first month. Less common side effects include fatigue, mild headache, and injection site reactions.

Serious but rare side effects include pancreatitis, gallbladder issues (gallstones, inflammation), and severe allergic reactions. Seek prompt medical attention for severe or persistent abdominal pain (especially radiating to the back), persistent vomiting, signs of dehydration, or signs of an allergic reaction (rash, swelling, difficulty breathing). For more on the safety profile, see the Cleveland Clinic Semaglutide reference. Dr. Qureshi reviews symptoms at virtual follow-up visits and adjusts the program if side effects are interfering with quality of life.

How much does it cost at Dr. Qureshi's office?

Cost is one of the most common barriers to GLP-1 therapy — and one reason Dr. Qureshi structures his program around generic compounded versions rather than brand-name retail products.

Cash pay starts at $100 per month for generic compounded Semaglutide or Tirzepatide. By comparison, brand-name Wegovy or Zepbound at retail without insurance often runs $1,000 to $1,500 per month — ten to fifteen times the cash-pay program cost.

GLP-1 medications prescribed for weight loss are typically not covered by commercial insurance. Some plans cover them when prescribed for type 2 diabetes (a different ICD code), but not for weight management. Coverage varies and changes frequently. Dr. Qureshi's office can help clarify your specific situation — reach out via the contact page with questions before your visit.

Should you consider GLP-1 medication?

GLP-1 medication is worth a serious conversation if you fit one or more of these patterns:

• You've tried diet and exercise repeatedly without sustained results
• You're carrying weight that is contributing to weight-related health concerns — joint pain, increased diabetes risk, sleep apnea, cardiovascular risk factors, or fatty liver
• You don't have any of the contraindications listed earlier (no personal/family history of medullary thyroid cancer or MEN-2; no history of pancreatitis; not pregnant or breastfeeding)
• You're ready to commit to ongoing medical management, including regular monitoring and the understanding that long-term success often means long-term treatment
• You want a structured, medically supervised path that doesn't involve surgery

The best next step is a consultation. Dr. Qureshi will review your health picture, discuss whether GLP-1 is the right fit, and walk you through realistic expectations. Visit the GLP-1 weight loss treatment page for a program overview, or call to book directly. If weight-related joint pain is a primary concern, you may also want to compare regenerative options — see our guide on PRP vs cortisone injections.

Frequently Asked Questions

How quickly will I lose weight on GLP-1 medication?

Most patients see noticeable weight loss within the first month. Average weight loss is 5-10+ pounds per month, though individual results vary. Long-term clinical data shows patients can lose up to 25% of body weight after 72 weeks of consistent treatment.

Is GLP-1 medication covered by insurance?

Coverage varies. GLP-1 medications prescribed for weight loss are typically not covered by commercial insurance. Some plans cover them when prescribed for type 2 diabetes. At Dr. Qureshi's Katy office, generic compounded GLP-1 medications start at $100 per month cash pay — substantially less than retail brand-name pricing.

What happens if I stop taking GLP-1 medication?

Weight regain is common when GLP-1 medications are discontinued, as the appetite-suppressing effect wears off. Long-term success typically requires continued use of medication, lifestyle changes, or both. Dr. Qureshi will discuss long-term planning with you during your treatment.

Can I take GLP-1 if I have a family history of cancer?

GLP-1 medications carry an FDA boxed warning regarding thyroid cancer risk and are not appropriate for patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN-2). For other types of cancer history, candidacy is reviewed individually based on the specific situation.

Do I need to follow a specific diet on GLP-1?

Dr. Qureshi's program does not prescribe a specific diet or include nutrition counseling. Most patients naturally eat less due to reduced appetite. Patients seeking structured nutrition support can be referred to dietitians or complementary programs.